# Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

> **NCT04349436** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Replimune, Inc.** · enrollment: 69 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Basal Cell Carcinoma
- Locally Advanced Cutaneous Squamous Cell Carcinoma
- Cancer

## Interventions

- **BIOLOGICAL:** RP1, intra-tumoral injection, oncolytic virus

## Key facts

- **NCT ID:** NCT04349436
- **Lead sponsor:** Replimune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-15
- **Primary completion:** 2029-07
- **Final completion:** 2029-11
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04349436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04349436, "Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04349436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*